Your browser doesn't support javascript.
CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
Ebrahimi, Narges; Mazdak, Mahsa; Shaygannejad, Vahid; Mirmosayyeb, Omid.
  • Ebrahimi N; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Mazdak M; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Shaygannejad V; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: v.shaygannejad@gmail.com.
  • Mirmosayyeb O; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Vaccine ; 41(5): 1003-1008, 2023 01 27.
Article in English | MEDLINE | ID: covidwho-2165938
ABSTRACT

BACKGROUND:

Several reports have been documented in possible association with the administration of different severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccines and central nervous system (CNS)demyelinating disorders, specifically post mRNA vaccines. We report twelve cases of developing Multiple sclerosis (MS) or Neuromyelitis Optica spectrum disorders (NMOSD) following neither the first nor second dose of inactivated or viral vector COVID-19 vaccine.

METHODS:

We retrospectively compiled twelve patients' medical information with a new onset of MS or NMOSD in their first six weeks following a COVID-19 vaccine.

RESULTS:

We report twelve cases of MS (n = 9), clinically isolated syndrome (CIS)(n = 1), and NMOSD (n = 2) following COVID-19 inactivated vaccines (n = 11) or viral vector vaccines (n = 1), within some days following either the first (n = 3), second dose (n = 8), or third dose (n = 1). Their median age was 33.3 years, ranging from 19 to 53 years. Ten were women (83 %). All patients fully (n = 5) or partially (n = 2) recovered after receiving 3 doses of Corticosteroids. Common medications were Natalizumab, Teriflunomide, Dimethyl fumarate, and Rituximab. Also, Interferon beta 1-a was administered to one patient with severe symptoms of numbness.

CONCLUSION:

Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Demyelinating Diseases / COVID-19 Vaccines / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male Language: English Journal: Vaccine Year: 2023 Document Type: Article Affiliation country: J.vaccine.2023.01.003

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Demyelinating Diseases / COVID-19 Vaccines / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male Language: English Journal: Vaccine Year: 2023 Document Type: Article Affiliation country: J.vaccine.2023.01.003